Why Oral Insulin Remains a Challenge: Barriers to Pill Formulation
Insulin is a peptide hormone that cannot be delivered effectively as a pill due to multiple physiological barriers. Despite decades of research, injectable insulin (pens, pumps) remains the standard.
Major Barriers
- Enzymatic degradation: Gastric pepsin, pancreatic proteases (trypsin, chymotrypsin) rapidly hydrolyze insulin into inactive fragments.
- Poor intestinal absorption: Insulin's large size (~5.8 kDa), hydrophilicity, and lack of specific transporters limit paracellular/transcellular uptake (<1% bioavailability).
- First-pass hepatic metabolism: Absorbed insulin enters portal circulation → liver extracts 50–80% before reaching systemic circulation.
- Instability: Sensitive to pH, temperature, agitation, and oxidation. Formulation must protect integrity through GI tract.
- Dosing precision: Insulin requires precise, individualized dosing; oral delivery variability risks hypoglycemia/hyperglycemia.
Current Research Strategies
- Enteric coatings, enzyme inhibitors (e.g., sodium caprate), nanoparticle encapsulation, mucoadhesive polymers, permeation enhancers.
- Oral insulin candidates in clinical trials (e.g., ORMD-0801, HDV-I) show modest bioavailability (~5–15%) but not yet approved for routine use.
- Alternative non-injectable routes: inhaled (Afrezza®), buccal, nasal, transdermal—each with own challenges.
Until bioavailability, consistency, and cost-effectiveness match injections, oral insulin remains experimental.
Diabetes - Related Articles
- Understanding and Preventing Type 2 Diabetes: A Comprehensive Guide
- Managing High Blood Sugar: Safe & Effective Strategies
- Byetta (Exenatide): Risks, Benefits & Important Considerations
- Diabetic Foot Care: Daily Checklist for Nursing Assistants
- Headaches and Glaucoma in Type 2 Diabetes: Symptoms & Risks
- Understanding TZD Medications for Type 2 Diabetes
- Intravenous Insulin Injection: Extreme Dangers, Mechanism, and Why It's Never Done Intentionally
